1.8(top 50%)
impact factor
4.6K(top 5%)
papers
85.9K(top 5%)
citations
102(top 5%)
h-index
1.8(top 50%)
impact factor
4.9K
all documents
89.0K
doc citations
143(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulatorsAnti-Cancer Drugs1996729
2Drug-polymer conjugatesAnti-Cancer Drugs1992435
3PI3K/Akt/mTOR pathway as a target for cancer therapyAnti-Cancer Drugs2005396
4Dendrimer-platinateAnti-Cancer Drugs1999394
5A systematic review of the anticancer properties of berberine, a natural product from Chinese herbsAnti-Cancer Drugs2009358
6Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrierAnti-Cancer Drugs2007343
7Triterpenoids as new promising anticancer drugsAnti-Cancer Drugs2009309
8Liposomal encapsulated anti-cancer drugsAnti-Cancer Drugs2005294
9Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell linesAnti-Cancer Drugs1997290
10Histone deacetylase inhibitors in cancer treatmentAnti-Cancer Drugs2002280
11Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part IAnti-Cancer Drugs1995252
12Targeting Stat3 in cancer therapyAnti-Cancer Drugs2005252
13Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxelAnti-Cancer Drugs2001246
14Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell linesAnti-Cancer Drugs1996239
15Preclinical characteristics of gemcitabineAnti-Cancer Drugs1995235
16NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agentAnti-Cancer Drugs2006228
17Consequences of angiogenesis for tumor progression, metastasis and cancer therapyAnti-Cancer Drugs1995217
18Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation studyAnti-Cancer Drugs2009214
19Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancersAnti-Cancer Drugs1997208
20Mitomycin CAnti-Cancer Drugs1990206
21Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assaysAnti-Cancer Drugs1995202
22Pilot phase l-ll study on 5-aza-2??-deoxycytidine (Decitabine) in patients with metastatic lung cancerAnti-Cancer Drugs1997198
23Gemcitabine—a safety reviewAnti-Cancer Drugs1998186
24Enhancement of cytotoxicity by electropermeabilizationAnti-Cancer Drugs1998185
25Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase–Akt/PKB survival pathwayAnti-Cancer Drugs2003183
26EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanismAnti-Cancer Drugs2005182
27Alternative drug formulations of docetaxel: a reviewAnti-Cancer Drugs2007181
28Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC statusAnti-Cancer Drugs2008181
29Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assemblyAnti-Cancer Drugs2003180
30Non-viral vectors in cancer gene therapy: principles and progressAnti-Cancer Drugs2001176
31Sesquiterpene lactones as drugs with multiple targets in cancer treatmentAnti-Cancer Drugs2012176
32COX-2 inhibitors in cancer treatment and prevention, a recent developmentAnti-Cancer Drugs2002169
33Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assayAnti-Cancer Drugs1996167
34Betulinic acid, a natural compound with potent anticancer effectsAnti-Cancer Drugs2010164
35The antioxidant caffeic acid phenethyl ester induces apoptosis associated with selective scavenging of hydrogen peroxide in human leukemic HL-60 cellsAnti-Cancer Drugs2001162
36Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytesAnti-Cancer Drugs2004162
37Mechanism of action of rituximabAnti-Cancer Drugs2002161
38Programmed cell death (apoptosis) and response to anti-cancer drugsAnti-Cancer Drugs1994153
39Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunitiesAnti-Cancer Drugs2009152
40Oral mucositisAnti-Cancer Drugs2011148
41Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel – a reviewAnti-Cancer Drugs2014147
42Anti-tumor effect of gallic acid on LL-2 lung cancer cells transplanted in miceAnti-Cancer Drugs2001146
43TaxolAnti-Cancer Drugs1991141
44PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cellsAnti-Cancer Drugs2009141
45Autophagy and doxorubicin resistance in cancerAnti-Cancer Drugs2018136
46Toxicity of anticancer agents mediated by electroporation in vitroAnti-Cancer Drugs2000135
47Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell linesAnti-Cancer Drugs1996134
48Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft modelsAnti-Cancer Drugs2004134
49Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjectsAnti-Cancer Drugs2006133
50Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancerAnti-Cancer Drugs2006133